Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin and ACE inhibitors

This article was originally published in The Tan Sheet

Executive Summary

Aspirin therapy for heart attack survivors does not negatively influence angiotensin-converting enzyme inhibitor (ACEi) treatment, according to an overview study published in the June issue of the Journal of the American College of Cardiology. Contrary to widespread concerns, "the present results support the early use of ACEi in acute [myocardial infarction], irrespective of whether or not [aspirin] is given," Roberto Latini, MD, Instituto di Richerche Farmacologiche, Milan, Italy, et al., conclude. Data relating to the use or non-use of aspirin were reviewed for nearly 97,000 patients; evidence of negative interactions did not surface, the report says. In an accompanying editorial, Donald Hall, MD, Technical University of Munich, Germany, says the study contradicts previous research and the results are undermined by the fact that the non-aspirin group was smaller and comprised older, sicker patients

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091297

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel